For example, KEYNOTE‐189 and KEYNOTE‐407, which encompassed patients with PD‐L1 all comers but different histologic subtypes (adenocarcinoma and squamous cell carcinoma, respectively), showed improved median PFS to 9 and 8 months, median OS to 22 and 17 months, and ORR to 48.3% and 62%, respectively, with first‐line combination pembrolizumab with chemotherapy. Here, CD274 is linked to squamous cell carcinoma.